Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Investor Presentation (April 2022)
18 slides from Radiopharm Theranostics's investor presentation, Apr 4, 2022
Slide 1: Dual Action LRRC15-Targeting Monoclonal Antibody from UCLA
For personal use only Further expanding one of the deepest pipeline in the sector with DUAL ACTION LRRC15-TARGETING MONOCLONAL ANTIBODY FROM UCLA April 2022 Riccardo Canevari CEO, Radiopharm Theranostics Ltd
Slide 2: Investment Highlights: In-licensing from UCLA
INVESTMENT HIGHLIGHTS In-licensing from UCLA For personal use only DUAL ACTION LRRC15-TARGETING MONOCLONAL ANTIBODY Sign on agreement Industry standard, low nominal value Development milestones Phase II, Phase III, FDA & EMA approval Royalties Low single digit LRRC15-targeting antibody “DUNP19” hold
Slide 3: The Technology & MoA
THE TECHNOLOGY & MoA For personal use only LRCC15 expression is produced by cancer cells LRRC15 production is very high in aggressive and AND the surrounding tumour micro- treatment-resistant tumours. environment, but not by healthy normal tissues. The LRRC15-targeted radiopharmaceutical The radionu
Slide 4: Inventor & Institution
INVENTOR & INSTITUTION Dr. David Ulmert, MD, PhD For personal use only Dr Ulmert obtained his degrees from Lund University, Sweden. He is currently lab head, faculty member and director of the preclinical theranostics program at the department of molecular and ▪ The University of California, Los Ang
Slide 5: Data – The Target: LRRC15
PRECLINICAL DATA – THE TARGET: Leucin Rich Repeat Containing Protein 15 (LRRC15) For personal use only R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 5
Slide 6: LRRC15 has very limited expression in healthy tissues
PRECLINICAL DATA – THE TARGET: LRRC15 has very limited expression in Healthy tissues For personal use only 1. Adrenocortical carcinoma 2. Bladder Urothelial Carcinoma 3. Breast invasive carcinoma 4. Cervical/endocervical carcinoma 5. Cholangio carcinoma 6. Colon adenocarcinoma 7. Lymphoid neoplasm/B
Slide 7: Data – The Molecule: Humanized Monoclonal Antibody DUNP19
PRECLINICAL DATA – THE MOLECULE: Humanized Monoclonal Antibody DUNP19 Unique MoA and very fast internalization For personal use only R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 7
Slide 8: mAb DUNP19 in Osteosarcoma in vivo model
PRECLINICAL DATA: mAb DUNP19 in Osteosarcoma in vivo model For personal use only R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 8
Slide 9: Osteosarcoma - single dose
PRECLINICAL DATA: mAb DUNP19 in Osteosarcoma in vivo model Osteosarcoma - single dose For personal use only R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 UNPUBLISHED DATA 9
Slide 10: Osteosarcoma - multiple doses
PRECLINICAL DATA: mAb DUNP19 in Osteosarcoma in vivo model Osteosarcoma - multiple doses For personal use only T Tx Tx Tx Tx Tx x R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 UNPUBLISHED DATA 10
Slide 11: mAb DUNP19 in Glioblastoma in vivo model
PRECLINICAL DATA: mAb DUNP19 in Glioblastoma in vivo model U118 (GBM) s.c. tumors For personal use only Tx Tx R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 UNPUBLISHED DATA 11
Slide 12: Clinical Development Plan: Overview
CLINICAL DEVELOPMENT PLAN: OVERVIEW For personal use only LRCC expression in Pancreatic, Breast, multiple tumor types Glioblastoma, Osteosarcoma…. High unmet medical need First indication selected: Orphan indication OSTEOSARCOMA (faster regulatory process) No competition (no radiopharmaceutical tria
Slide 13: High unmet need when LRRC15 is highly expressed
CLINICAL DEVELOPMENT PLAN: High unmet need when LRRC15 is highly expressed For personal use only R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 Cui et al. J. Orthop.Res, 2020. 13
Slide 14: Osteosarcoma (OS): LRRC15
Osteosarcoma (OS): LRRC15 For personal use only • Primarily a disease of children and adolescents o 8th most common cancer in children • Painful, disfiguring, and often rapidly fatal: o 8% originate in face o one of the very few cancers that metastasizes to the face Treatment is wide surgical excisi
Slide 15: Market & Competition
MARKET & COMPETITION For personal use only KEY STATISTICS FOR THERAPEUTIC OPTIONS COMPETITION OSTEOSARCOMA Osteosarcoma is No targeted therapies approved Surgery linked to very poor prognosis in Osteosarcoma by FDA No radiopharmaceutical Each year, about 1,000 new cases Chemotherapy therapies report
Slide 16: Manufacturing & IP
MANUFACTURING & IP For personal use only mAb manufacturing IP INNOVAGEN AB • First patent number SE-22370 Lund 63/003,598 filed 18 Mar 2020 Sweden • Patent number P-594449-PC claims priority • Worldwide coverage • Expected loss of exclusivity March 2041 R AD I O P H A R M T H E R A N O S T I C S L T
Slide 17: Summary
SUMMARY ▪ High potential radiopharmaceutical therapy in-licenced by top institution (UCLA) For personal use only ▪ Targeting LRCC15, expressed in multiple tumor types ▪ Unique DUAL ACTION against the tumor and its microenvironment ▪ Potential first in class in high unmet medical need disease (Osteos
Slide 18: Contact Us
For personal use only CONTACT US Riccardo Canevari Paul Hopper CEO & MANAGING DIRECTOR Executive Chairman Radiopharm Theranostics Limited Radiopharm Theranostics Limited T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranost
Radiopharm Theranostics — Investor Presentation (April 2022) on 6ix